In this study, we identified for the first time the activation of YAP as a potential therapeutic target for overcoming acquired resistance to ALK‐TKI in ALK‐rearranged NSCLC using cell lines, mouse models, and patient samples. This evidence concerns the gene ALK and non-small cell lung carcinoma.